• Relay Therapeutics recently reported encouraging Phase 1/2 data for its lead asset zovegalisib in heavily pre-treated PI3Ka‑mutated HR+/HER2- metastatic breast cancer and outlined plans, subject to regulatory feedback, to launch a Phase 3 trial in collaboration with Pfizer’s investigational CDK4 inhibitor atirmociclib.
• At the same time, Relay is seeking shareholder approval to increase its authorized common stock pool and is seeing strong interest from Wall Street analysts, underscoring how its precision oncology platform and expanding zovegalisib program are reshaping expectations for the company’s role in HR+/HER2- breast cancer and PI3Ka‑driven diseases.
• Against this backdrop of zovegalisib’s triplet data and Phase 3 ambitions, we’ll examine how the update influences Relay Therapeutics’ investment narrative.

Find 49 companies with promising cash flow potential yet trading below their fair value.

What Is Relay Therapeutics' Investment Narrative?

To own Relay Therapeutics, you need to believe that zovegalisib can become a cornerstone precision therapy in PI3Ka‑mutated HR+/HER2- breast cancer and potentially other PI3Ka‑driven diseases, and that Relay can fund that journey without excessively diluting shareholders. The latest triplet data and Phase 3 plans, plus supportive analyst commentary, keep clinical progress and regulatory milestones as the core near term catalysts, with the upcoming Q1 2026 update and Phase 3 design feedback in focus. The two fresh developments slot into that story in different ways: the proposed increase in authorized shares flags future financing overhang as Relay leans into an expanded zovegalisib program, while the departure of Dr. Sekar Kathiresan looks immaterial to near term catalysts given an already seasoned board and management team.

Yet the same share increase that enables growth could also magnify dilution risk investors should not ignore.

Our valuation report here indicates Relay Therapeutics may be overvalued.

Exploring Other Perspectives

One Simply Wall St Community member places fair value at US$21. With Relay’s ambitious zovegalisib Phase 3 plans and the proposed expansion of the share pool, you will want to weigh dilution risk against those clinical catalysts using multiple viewpoints.

Explore another fair value estimate on Relay Therapeutics - why the stock might be worth as much as 65% more than the current price!

The Verdict Is Yours

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Relay Therapeutics research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Relay Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Relay Therapeutics' overall financial health at a glance.

Contemplating Other Strategies?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Uncover the next big thing with 23 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.